MK-3415A
Biological
Merck Sharp & Dohme Corporation
Total Payments
$492,235
Transactions
14
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $195,598 | 6 | 1 |
| 2017 | $296,637 | 8 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $483,829 | 10 | 98.3% |
| Travel and Lodging | $7,581 | 2 | 1.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $824.50 | 2 | 0.2% |
Payments by Type
Research
$483,829
10 transactions
General
$8,406
4 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| THE DEVELOPMENT OF PREDICTIVE MODELS OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION | Merck Sharp & Dohme Corporation | $245,845 | 0 |
| A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 Human Monoclonal Antibody to Clostridium difficile toxin A, MK-6072 Human Monoclonal Antibody to Clostridium difficile toxin B, and MK-3415A Human Monoclonal Antibodies to C. difficile toxin A and toxin B in Patients Receiving Antibiotic Therapy for Clostridium difficile Infection MODIFY I | Merck Sharp & Dohme Corporation | $86,462 | 0 |
| A Study to Evaluate the Immune Response to Clostridium difficile in Adult Immunosuppressed Patients with Clostridium difficile Infection | Merck Sharp & Dohme Corporation | $57,494 | 0 |
| How does passive immunoglobulin effect C. difficile toxin A and B binding and host barrier response | Merck Sharp & Dohme Corporation | $47,402 | 0 |
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-6072 Human Monoclonal Antibody to C. difficile toxin B, and MK-3415A Human Monoclonal Antibodies to C. difficile toxin A and toxin B in Patients Receiving Antibiotic Therapy for C. difficile Infection MODIFY II | Merck Sharp & Dohme Corporation | $40,843 | 0 |
| Clostridium difficile colitis in pediatric small bowel transplant recipients epidemiology, risk factors and outcome | Merck Sharp & Dohme Corporation | $5,783 | 0 |
Top Doctors Receiving Payments for MK-3415A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Omaha, NE | $483,829 | 10 |
| Kathleen Mullane | Infectious Disease | Burr Ridge, IL | $7,276 | 2 |
| , MD | Gastroenterology | Cincinnati, OH | $1,130 | 2 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $492,235
Product Information
- Type Biological
- Total Payments $492,235
- Total Doctors 2
- Transactions 14
About MK-3415A
MK-3415A is a biological associated with $492,235 in payments to 2 healthcare providers, recorded across 14 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $195,598 was paid across 6 transactions to 1 doctors.
The most common payment nature for MK-3415A is "Unspecified" ($483,829, 98.3% of total).
MK-3415A is associated with 6 research studies, including "THE DEVELOPMENT OF PREDICTIVE MODELS OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION" ($245,845).